2 active not recruiting. 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Active not recruiting 2 |
Follow Anlotinib: new trials by email Literature Review of Anlotinib trials Research Report on Anlotinib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Anlotinib Combined With Carboplatin/Paclitaxel as First-line Treatment in Patients With Advanced Ovarian Cancer Drug: Anlotinib, Drug: Carboplatin/Paclitaxel - Ovarian Neoplasms, Fallopian Tube Neoplasms | Phase 2 | Active not recruiting | Wenjun Cheng | 56 | 2021-08-24 | 2024-07-03 |
| Neoadjuvant PD-1 Inhibitor (Sintilimab), Anlotinib Combined With Chemotherapy in Resectable Stage IIA-IIIB NSCLC Neoadjuvant therapy 1 - Sintilimab, Lung Cancer | Phase 2 | Active not recruiting | Tang-Du Hospital | 45 | 2021-03-01 | 2024-10-18 |
Carcinoma (1) · Carcinoma, Ovarian Epithelial (1) · Endocrine System Diseases (1) · Fallopian Tube Neoplasms (1) · Genital Diseases, Female (1) · Genital Neoplasms, Female (1) · Lung Neoplasms (1) · Neoplasms by Histologic Type (1) · Neoplasms by Site (1) · Neoplasms, Glandular and Epithelial (1) · Ovarian Diseases (1) · Ovarian Neoplasms (1)
Neoplasms (2) · Adnexal Diseases (1) · Endocrine Gland Neoplasms (1) · Fallopian Tube Diseases (1) · Female Urogenital Diseases (1) · Female Urogenital Diseases and Pregnancy Complications (1) · Genital Diseases (1) · Gonadal Disorders (1) · Lung Diseases (1) · Neoplasms by Site (1) · Respiratory Tract Diseases (1) · Respiratory Tract Neoplasms (1) · Thoracic Neoplasms (1) · Urogenital Diseases (1) · Urogenital Neoplasms (1)
anlotinib (2) · CP protocol (1) · Drug Therapy (1) · sintilimab (1)
Tang-Du Hospital (1) · Wenjun Cheng (1)
China (2)